13D Filing: Elliott Associates and American Capital, Ltd (ACAS)
– insidermonkey.com
Paul Singer‘s Elliott Associates has recently filed a 13D filing, in which it revealed its activist position in American Capital Ltd. (NASDAQ:ACAS). According to the filing, Elliott Management owns some 6.46 million shares, which represent 2.5% of the company’s outstanding common stock…
23,144 Ways America Created Terrorists In 2015
– zerohedge.com/
Submitted by Don Shay via TheAntiMedia.org, According to the Council of Foreign Relations, a pro-government think tank, the Obama Administration in the last year alone has dropped over 23,144 bombs on predominantly Muslim countries. Whether or not one believes the force is justified on any pragmatic grounds, the carnage is irrefutable…
34 Charts: This Time Is Different
– cfainstitute.org
Growth will come, but be realistic. It might take a while. Read more
20 Tallest Buildings Completed in 2015
– ritholtz.com
Source: NY Mag
The post 20 Tallest Buildings Completed in 2015 appeared first on The Big Picture.
Financial Engineering Chart of the Day: Fed Balance Sheet vs. S&P 500
– globaleconomicanalysis.blogspot.com
Fed Balance Sheet vs. S&P 500I was playing around with some ideas on the St Louis Fed “Fred” database and came up with this.Mike “Mish” ShedlockMike “Mish” Shedlock is a registered investment advisor representative for SitkaPacific Capital Management. Sitka Pacific is an asset management firm whose goal is strong performance and low volatility, regardless of market direction…Biogen Earns $4.50 per Share
– crossingwallstreet.com
Biogen (BIIB) crushed their earnings estimates. For Q4, the biotech company earned $4.50 per share which was 42 cents better than estimates.
Revenue increased 7.5% to $2.84 billion, above the $2.71 billion analysts had forecast. The company cited the solid performance from its multiple sclerosis drugs and the strong adoption of its hemophilia therapies…
Revenue increased 7.5% to $2.84 billion, above the $2.71 billion analysts had forecast. The company cited the solid performance from its multiple sclerosis drugs and the strong adoption of its hemophilia therapies…
from Royalty Gateway http://www.royaltygateway.com/34-charts-this-time-is-different-more-520-pm-jan-27th/
13D Filing: Elliott Associates and American Capital, Ltd (ACAS)
– insidermonkey.com
Paul Singer‘s Elliott Associates has recently filed a 13D filing, in which it revealed its activist position in American Capital Ltd. (NASDAQ:ACAS). According to the filing, Elliott Management owns some 6.46 million shares, which represent 2.5% of the company’s outstanding common stock…
23,144 Ways America Created Terrorists In 2015
– zerohedge.com/
Submitted by Don Shay via TheAntiMedia.org, According to the Council of Foreign Relations, a pro-government think tank, the Obama Administration in the last year alone has dropped over 23,144 bombs on predominantly Muslim countries. Whether or not one believes the force is justified on any pragmatic grounds, the carnage is irrefutable…
34 Charts: This Time Is Different
– cfainstitute.org
Growth will come, but be realistic. It might take a while. Read more
20 Tallest Buildings Completed in 2015
– ritholtz.com
Source: NY Mag
The post 20 Tallest Buildings Completed in 2015 appeared first on The Big Picture.
Financial Engineering Chart of the Day: Fed Balance Sheet vs. S&P 500
– globaleconomicanalysis.blogspot.com
Fed Balance Sheet vs. S&P 500I was playing around with some ideas on the St Louis Fed “Fred” database and came up with this.Mike “Mish” ShedlockMike “Mish” Shedlock is a registered investment advisor representative for SitkaPacific Capital Management. Sitka Pacific is an asset management firm whose goal is strong performance and low volatility, regardless of market direction…Biogen Earns $4.50 per Share
– crossingwallstreet.com
Biogen (BIIB) crushed their earnings estimates. For Q4, the biotech company earned $4.50 per share which was 42 cents better than estimates.
Revenue increased 7.5% to $2.84 billion, above the $2.71 billion analysts had forecast. The company cited the solid performance from its multiple sclerosis drugs and the strong adoption of its hemophilia therapies…
Revenue increased 7.5% to $2.84 billion, above the $2.71 billion analysts had forecast. The company cited the solid performance from its multiple sclerosis drugs and the strong adoption of its hemophilia therapies…
No comments:
Post a Comment